Bacterial meningitis is a serious infection of the central nervous system that affects people all over the world. Streptococcus pneumoniae and Neisseria meningitidis are the most common pathogens causing meningeal inflammation in Europe. Treatment with standard antibiotics is becoming ineffective, not only due to their inability to cross the blood-brain barrier, but also due to rising antibiotic resistance. As a result, novel therapeutics to combat the infection are required. A promising solution could be therapeutic nanomolecules, such as dendrimers, some of which have antimicrobial properties due to their chemical structure. Additionally, they may be decorated with a suitable therapeutic and central nervous system homing peptides to construct nano-drug delivery systems, which can effectively cross the blood-brain barrier. To synthesize safe dendrimeric nano-drug delivery system it is necessary to select the best dendrimer candidates with antimicrobial activity and to understand pharmacosafety, pharmacokinetics and dynamics. This review provides a brief overview of dendrimers and their antimicrobial properties as they have been studied in relation to the blood-brain barrier and existing antibiotics.
